Opendata, web and dolomites

CASI

AN INTEGRATED AUTOMATED ECG DIAGNOSTICS PLATFORM TO IMPROVE CARDIAC SAFETY IN CLINICAL DRUG TRIALS

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CASI project word cloud

Explore the words cloud of the CASI project. It provides you a very rough idea of what is the project "CASI" about.

companies    delays    mandated    grown    university    fits    manufactures    56m    consistency    purpose    conducting    strategy    ten    data    validation    customers    capability    solution    70    ago    designs    vitalograph    pharmaceutical    incorporating    mdd    licensing    renowned    unnecessary    automated    place    legislation    sells    12    services    approvals    regulated    margin    successfully    segment    device    algorithms    expensive    certifications    buying    totalling    6bn    solutions    bandwidth    introduce    commercial    glasgow    medical    csa    world    customer    trials    few    capacity    validate    drug    poor    50    operates    heavily    3rd    reducing    revenue    entering    time    jurisdictions    dual    anticipated    clinical    market    participated    party    safety    cardiac    regulatory    group    cfda    ecg    fda    cut    ant    diagnostics    skills    settings    jpal    minutes    days    ce    algorithm    25    company    ip    focusses    whilst   

Project "CASI" data sheet

The following table provides information about the project.

Coordinator
VITALOGRAPH (IRELAND) LIMITED 

Organization address
address: MILL HOUSE HENRY STREET
city: LIMERICK
postcode: V94
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-03-01   to  2015-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VITALOGRAPH (IRELAND) LIMITED IE (LIMERICK) coordinator 50˙000.00

Map

 Project objective

Vitalograph is a 50 year old company, that designs, manufactures and sells medical devices in clinical settings and clinical drug trials. This proposal focusses on the validation of a new dual-purpose 12 lead ECG diagnostics device incorporating an automated algorithm to be used in the regulatory mandated cardiac safety elements of clinical drug trials. Current solutions are expensive, introduce unnecessary analysis delays and have poor data consistency. The proposed solution can cut customer costs by 50% whilst at the same time improving Vitalograph’s margin from 25% to 70% as well as reducing the analysis time from several days to a few minutes. The target market has grown to be greater than €1.6Bn in 10 years with the targeted segment being one third of this. The target customers are pharmaceutical companies conducting drug trials The project fits well with Vitalograph’s product and market strategy to develop new medical devices for clinical drug trials and will increase the available market by a factor of 10. The company already operates successfully within the market having participated in over 50 trials totalling €56m in revenue since entering the market ten years ago. It has the R&D skills and bandwidth, operational capacity and commercial capability to fully exploit the resultant offering. Vitalograph has already established a market in cardiac safety in clinical trials by buying in other devices and services. Vitalograph will work with the world-renowned Glasgow University ECG group as a 3rd party to validate their existing clinical algorithms for automated use in clinical drug trials. An IP licensing agreement is already in place and no IP issues are anticipated. The market is heavily regulated under medical device legislation in all jurisdictions (CE MDD, FDA, CSA, JPAL, CFDA etc.) but Vitalograph already has the necessary approvals, experience, regulatory knowledge and certifications to bring this product to the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CASI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CASI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More